CN102796156B - Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof - Google Patents
Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof Download PDFInfo
- Publication number
- CN102796156B CN102796156B CN201210314213.2A CN201210314213A CN102796156B CN 102796156 B CN102796156 B CN 102796156B CN 201210314213 A CN201210314213 A CN 201210314213A CN 102796156 B CN102796156 B CN 102796156B
- Authority
- CN
- China
- Prior art keywords
- camp
- meglumine
- compound
- preparation
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003194 meglumine Drugs 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- -1 meglumine compound Chemical class 0.000 title abstract description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title abstract 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 208000009525 Myocarditis Diseases 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010040639 Sick sinus syndrome Diseases 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002963 ganciclovir Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 229940090044 injection Drugs 0.000 description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- HYMXALLEHXXORK-HTDNVCFESA-N (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 HYMXALLEHXXORK-HTDNVCFESA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940068274 adenosine injection Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an adenosine cyclophosphate double-molecule meglumine compound and a preparation method thereof, and provides a compound formed by 1 molecule of adenosine cyclophosphate and 2 molecules of meglumine, a preparation method thereof and a medicinal composition comprising the denosine cyclophosphate double-molecule meglumine compound. The water solubility and the stability of the compound are more excellent than those of the conventional compounds.
Description
Technical field
The present invention relates to a kind of cAMP two meglumine compounds and preparation method thereof, belong to the synthetic field of pharmaceutical chemistry.
Background technology
CAMP is a kind of protein kinase activator, belongs to the derivative of Nucleotide.It is a kind of important substance with physiologically active extensively existing in human body, is generated under adenosine cyclase catalysis by Triphosaden, can regulate the several functions activity of cell.As the second messenger of hormone, in cell, bring into play the effect of hormone regulation physiological function and substance metabolism, change the function of cytolemma, impel the calcium ion in sarcoplasm matter to enter myofiber, thereby enhancing myocardial contraction, and promote the oxidasic activity of respiratory chain, and improve myocardial anoxia, alleviate coronary heart disease symptom and improve electrocardiogram(ECG.In addition, synthetic adjusting to sugar, metabolism of fat, nucleic acid, protein etc. plays an important role.
Meglumine, molecular weight is 195, soluble in water, there is suitable alkalescence and certain reductibility, and safe, nontoxic, with the compound combination that contains phenolic hydroxyl group, after salify to skin, mucous membrane, organize nonirritant, therefore be suitable as very much the solubility promoter of medicine, improve the water-soluble of principal constituent.
CAMP is slightly soluble in water, adds meglumine can increase its solvability in cAMP.Meglumine Adenosine Cyelophosphate (1: 1 compound of cAMP and meglumine, chemical name: meglumine cyclic adenylate, be called for short MCA, trade(brand)name, meglumine cyclic adenylate, MCA) injection liquid, be a kind of cardiac drug, be used for the treatment of heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis, and ARR assisting therapy.Because of its determined curative effect, effect is unique in recent years, and security is good, is widely used in clinical.But it is water-soluble, stability is still not enough, impurity showed increased in the time of standing storage, and also it is water-soluble not, can not be used for oral preparations etc.Therefore this area also needs a kind of stable cAMP medicine, can be for the applicable illness of cAMP, and Simultaneous Stabilization, safety, effective, good water solubility.
Summary of the invention
The object of the invention is to address the above problem, the compound of a kind of cAMP and meglumine is provided, i.e. cAMP two meglumine compounds, this compound is safer, stable, effective, has better water-soluble simultaneously.
Another object of the present invention is to provide the preparation method of described compound.
The present invention also provides a kind of pharmaceutical composition, and it comprises described compound and pharmaceutically acceptable carrier.
Another object of the present invention is to provide the application of described compound in preparation treatment heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis and antiarrhythmic medicament.
As previously mentioned, it is known in the art that cAMP and meglumine share, and their 1: 1 salifies are for injection.But in Meglumine Adenosine Cyelophosphate solution, along with the prolongation of shelf time, cAMP can be separated out gradually, liquid is occurred rotten, muddy, as changing small being difficult for, it is discovered, there will be serious untoward reaction if deliver medicine to patient, thereby affect the curative effect of medicine, affect the security of medication simultaneously.Meglumine cyclic adenosine injection is in solution state preservation process, easily meeting light changes, make drug degradation, because its clinical anaphylaxis increase, curative effect decline, and Meglumine Adenosine Cyelophosphate solution is subject to the affecting oxidation, polymerization of environmental factors and medicines structure is changed.
The inventor, through concentrating on studies, finds, under 60-70 DEG C of heating 0.5-2 hour, the meglumine of 1 molecule cAMP and 2 molecules to be synthesized to a compound.Find by analysis, under heating condition, meglumine not only with the phosphatase reaction of cAMP, and can react with the weakly acidic phenolic group of embodiment, cAMP two meglumine compounds are so just formed, the compound stability forming and water-soluble better is better cAMP medicinal forms.And the control of temperature is critical, temperature is too low, can not form described compound, only may form 1: 1 compound; Excess Temperature, has impact to the stability of cAMP and meglumine self, and impurity is too much.Based on above-mentioned discovery, complete the present invention.
Described compound structure is as follows:
The preparation method of compound of the present invention, simple process, it comprises:
Meglumine and DMF are joined in cAMP suspension and stirred, then at 60-70 DEG C, be heated to clarification, the direct described compound of acquisition after lyophilize.
Wherein, described cAMP suspension joins cAMP in water, methyl alcohol or ethanol and is prepared from, and the mol ratio of meglumine and cAMP is 2-10: 1.Usually, be 0.5-2 hour heat-up time.
The present invention also provides a kind of pharmaceutical composition, and it comprises described compound and pharmaceutically acceptable carrier, can be mixed with the form through any suitable administration, can prepare pharmaceutically acceptable any pharmaceutical dosage form, comprises injection, for example powder pin, injection liquid; Oral preparations, such as tablet, capsule, granule, oral liquid, powder agent, pill, sublingual administration agent etc.; Parenteral eye drop, nasal drops, [Dan etc. can be also the controlled release agent types of above various formulations.
Pharmaceutical carrier can comprise vehicle or thinner, for example, in Microcrystalline Cellulose, lactose, pregelatinized Starch, starch, dextrin, calcium phosphate, sucrose, dextran, N.F,USP MANNITOL, sorbyl alcohol, glucose, fructose, water, polyoxyethylene glycol, propylene glycol, glycerine, cyclodextrin, cyclodextrin derivative one or more; Tackiness agent, for example, in polyvinylpyrrolidone, methylcellulose gum, Walocel MT 20.000PV, HPMC, hydroxypropylcellulose, Natvosol, gelatin, guar gum, xanthan gum one or more; Lubricant, for example, in Magnesium Stearate, stearic acid, talcum powder, stearyl fumarate, Sodium Lauryl Sulphate BP/USP one or more; Disintegrating agent, for example, in sodium starch glycolate, low-substituted hydroxypropyl cellulose, Xylo-Mucine, cross-linked polyvinylpyrrolidone, croscarmellose sodium, crosslinked carboxymethyl fecula sodium, pregelatinized Starch one or more; Tensio-active agent, for example, in sodium lauryl sulphate, Tween-80 one or more; PH adjusting agent or buffer reagent, one or more of for example phosphate buffered saline buffer, citric acid, Trisodium Citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide; Sanitas, for example, in Sodium Benzoate, potassium sorbate, methyl p-hydroxybenzoate, propylparaben one or more; Stablizer and oxidation inhibitor, for example, in Calcium Disodium Edetate, S-WAT, vitamins C one or more; Seasonings, for example, in maltose alcohol, fructose, sucrose, soluble saccharin, flavoring orange essence, strawberry flavour one or more; And other auxiliary material.
It is also understood that in the time that formulation is tablet or capsule, can be film dressing.For the material of film dressing, comprise applicable Drug coating, for example HPMC, Natvosol, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate; Softening agent, for example polyoxyethylene glycol, triethyl citrate; Solubilizing agent, as Polyoxyethylene Sorbitan Monooleate; Pigment, as titanium dioxide, various ferric oxide, pink pigment, etc.
Pharmaceutical composition as above can also comprise other and have the material of pharmaceutical active, and for example, for the medicine of disease as mentioned above, the pharmaceutical composition that forms a kind of compound carrys out combination therapy.
The advantage of compound of the present invention is that it is water-soluble, stability is better, has also kept the activity of cAMP self simultaneously, and this is that it is with respect to cAMP and the outstanding feature of cAMP one meglumine salt.This is useful especially for preparation and storage pharmaceutical preparation.
Compound of the present invention has the pharmacological action identical with cAMP.In heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis and ARR correlation model, by described salt and cAMP and cAMP one comparing property of meglumine salt test, find that they have substantially suitable effect, do not exist notable difference.This shows, is consistent with the knowledge of this area, and salify can't change the activity of medicine.
Compound water soluble of the present invention, stability are better, and preparation method is easy, are applicable to scale operation, are suitable for preparing various types of pharmaceutical dosage forms, for effective application of cAMP provides better selection.
Embodiment
Be further detailed below by embodiment, but the present invention is not limited in these embodiment.
Embodiment 1. cAMP two meglumines and preparations thereof
Getting 0.30g (0.911mmol) cAMP adds in 20ml ethanol, stir and heat and make to dissolve completely, add wherein 0.49g (2.53mmol) meglumine, slowly add and stir, after completing, at 65 DEG C, heat 1.8 hours, to solution clarification, lyophilize, obtain the cAMP two meglumine 0.607g (yields: 93.5%) of white powder.
1HNMR(DMSO-d
6)δ(ppm)：0.767～0.785(4H，t)，1.134～1.160(21H，m)，1.450～1.466(4H，m)，2.514(4H，s)，2.815～2.843(2H，m)，2.946～2.997(2H，m)，3.312～3.319(4H，m)，3.385～3.427(8H，m)，3.640～3.654(6H，m)，3.835～3.844(2H，m)，3.931～3.952(4H，m)，4.154(2H，s)，4.371(2H，s)，6.658～6.616(6H，m)，7.082(2H，d)。
13CNMR(DMSO-d
6)δ(ppm)：13.967，22.117，25.597，29.137，31.289，33.289，51.435，53.465，63.461，66.956，67.719，68.864，70.283，113.474，121.044，130.304，141.446。
Embodiment 2. cAMP two meglumines and preparations thereof
Getting 0.50g (1.519mmol) cAMP adds in 35ml water, stir and heat and make to dissolve completely, add wherein 1.20g (6.148mmol) meglumine, slowly add and stir, after completing, at 70 DEG C, heat 0.8 hour, to solution clarification, lyophilize, obtain the cAMP two meglumine 0.987g (yields: 90.8%) of white powder.
CAMP two meglumines of above-mentioned preparation or its hydrate, through proton nmr spectra, carbon spectrum analysis, are all consistent with embodiment 1.
Embodiment 3. Accelerated stability tests
CAMP at high temperature can decompose conventionally, produces impurity impurity, is referred to as total related substance, under hot conditions, measures the wherein content of total related substance, analyzes its stability.
Get in 50 DEG C of baking ovens of appropriate cAMP two meglumine, respectively at sampling in the 5th, 10 days, measure total related substance wherein.
Adopt high-efficient liquid phase chromatogram technique analysis, test-results is in table 1.
Table 1
Measurement result shows, 50 DEG C of cAMP two meglumine high temperature are placed 10 days, and total its related substances increases to some extent, but that the overwhelming majority still keeps is stable, more more stable than cAMP one meglumine.
Embodiment 4. soluble tests
Through rough determination comparison, cAMP two meglumines and cAMP water-soluble (normal temperature and pressure) are compared as follows table 2.
Table 2
| Compound | Water-soluble (mg/ml water) |
| CAMP two meglumines | Be less than 1 |
| CAMP one meglumine | Be greater than 8 |
| CAMP | Be greater than 20 |
As can be seen from Table 2, the water-soluble cAMP that is far longer than of cAMP two meglumines of the present invention, is also greater than cAMP one meglumine, shows the water-soluble of excellence.
The lyophilized injectable powder of embodiment 4. cAMP two meglumines
| CAMP two meglumines | 30g |
| N.F,USP MANNITOL | 120g |
| Buffer reagent | In right amount |
| Water for injection | Add to 2500ml |
CAMP two meglumines, the N.F,USP MANNITOL of getting recipe quantity add 2300ml water for injection and dissolve, regulating pH is 5～6, injects water to 2500ml, with filtering with microporous membrane degerming, under hundred grades of conditions, carry out in sterile filling to 1000 cillin bottle, check after loading amount and add plug, box out, glass bottle is sent into in the freeze drying box of having sterilized, to carry out freeze-drying dry, pre-freeze 5 hours, temperature drops to-35 DEG C, distils for the first time 8 hours, and temperature rise is to-5 DEG C; Distil for the second time 7 hours, temperature rise to 25 DEG C, takes out after vacuum gland or inflated with nitrogen gland, and jewelling lid labeling gets product, and every bottle of freeze-dried powder is containing cAMP two meglumine 30mg.
Embodiment 5. cAMP two meglumine injections
Meglumine cyclic adenylate salt described in embodiment 1-2 and conventional pharmaceutical excipient are mixed, press the preparation method of injection, be prepared into freeze-dried powder injection or injection liquid, the meglumine cyclic adenylate salt that every bottle of freeze-dried powder injection or injection liquid contain 0.1～500mg.
Embodiment 6. cAMP two meglumine tablet/capsules
Meglumine cyclic adenylate salt described in embodiment 1-2 and conventional pharmaceutical excipient are mixed, by the preparation method of tablet or capsule, be prepared into tablet or capsule, the meglumine cyclic adenylate salt that every tablet or capsule contain 0.1～500mg.
Claims (6)
1. the cAMP being shown below and the compound of meglumine, its meglumine by 1 molecule cAMP and 2 molecules forms
。
2. the preparation method of the compound of claim 1, comprising: meglumine is joined in cAMP suspension and stirred, then at 60-70 DEG C, be heated to clarification, directly obtain described compound after lyophilize; Wherein the mol ratio of meglumine and cAMP is 2-10: 1.
3. the preparation method of claim 2, wherein said cAMP suspension joins cAMP in water, methyl alcohol or ethanol and is prepared from.
4. the arbitrary preparation method of claim 2-3, be wherein 0.5-3 hour heat-up time.
5. a pharmaceutical composition, the compound that comprises claim 1 and pharmaceutically acceptable carrier.
6. the application of the compound of claim 1 in preparation treatment heart failure, sick sinus syndrome, coronary heart disease, myocarditis and ARR medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210314213.2A CN102796156B (en) | 2012-08-24 | 2012-08-24 | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210314213.2A CN102796156B (en) | 2012-08-24 | 2012-08-24 | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102796156A CN102796156A (en) | 2012-11-28 |
| CN102796156B true CN102796156B (en) | 2014-07-30 |
Family
ID=47195487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210314213.2A Active CN102796156B (en) | 2012-08-24 | 2012-08-24 | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102796156B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103613626B (en) * | 2013-11-29 | 2015-10-14 | 湖北美林药业有限公司 | A kind of adenosine cyclophosphate compound and meglumine adenosine cyclophosphate medicine composition thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS49116096A (en) * | 1972-07-25 | 1974-11-06 | ||
| US3872082A (en) * | 1971-05-19 | 1975-03-18 | Boehringer Mannheim Gmbh | Substituted purineribofuranoside-3,5-cyclophosphate compounds and process for their preparation |
| CN1459288A (en) * | 2003-06-18 | 2003-12-03 | 赵琛 | Cyclophosphadenosine glucosamine infusion prepn., and its prepn. process, and method for testing contents thereof |
| CN1579413A (en) * | 2004-02-11 | 2005-02-16 | 江卫世 | Meglumine adenosine cyclophosphate for injection and its preparing method |
| CN1923180A (en) * | 2006-09-22 | 2007-03-07 | 江苏万邦生化医药股份有限公司 | Meglumine cyclic adenosine for injecta and its preparing process |
| CN101455631A (en) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | Meglumine cyclic adenosine injection and preparation technique thereof |
| CN102258531A (en) * | 2011-04-12 | 2011-11-30 | 宁辉 | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof |
| CN102488650A (en) * | 2011-12-19 | 2012-06-13 | 王保明 | Adenosine cyclophosphate pharmaceutical composition and preparation method thereof |
-
2012
- 2012-08-24 CN CN201210314213.2A patent/CN102796156B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3872082A (en) * | 1971-05-19 | 1975-03-18 | Boehringer Mannheim Gmbh | Substituted purineribofuranoside-3,5-cyclophosphate compounds and process for their preparation |
| JPS49116096A (en) * | 1972-07-25 | 1974-11-06 | ||
| CN1459288A (en) * | 2003-06-18 | 2003-12-03 | 赵琛 | Cyclophosphadenosine glucosamine infusion prepn., and its prepn. process, and method for testing contents thereof |
| CN1579413A (en) * | 2004-02-11 | 2005-02-16 | 江卫世 | Meglumine adenosine cyclophosphate for injection and its preparing method |
| CN1923180A (en) * | 2006-09-22 | 2007-03-07 | 江苏万邦生化医药股份有限公司 | Meglumine cyclic adenosine for injecta and its preparing process |
| CN101455631A (en) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | Meglumine cyclic adenosine injection and preparation technique thereof |
| CN102258531A (en) * | 2011-04-12 | 2011-11-30 | 宁辉 | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof |
| CN102488650A (en) * | 2011-12-19 | 2012-06-13 | 王保明 | Adenosine cyclophosphate pharmaceutical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102796156A (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3889481B2 (en) | Pharmaceutical composition | |
| CN102391250A (en) | Dabigatran compound and preparation method and medicinal composition thereof | |
| US20230190732A1 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| CN101585859B (en) | Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof | |
| CN104719910A (en) | Solid dispersion combination of EGCG (epigallocatechin gallate) with thermal stability and preparation method of solid dispersion combination and application in preparation of solid dispersion combination | |
| TWI343262B (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| CN100584835C (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
| CN102481287B (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
| JP3253302B2 (en) | Parenteral solution containing 3-dialkylaminoethoxybenzoyl-benzofuran | |
| CN100490819C (en) | Medicines of different characters and their preparation and use | |
| CN102796156B (en) | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof | |
| CN103980279B (en) | A kind of methotrexate compound and methotrexate for injection | |
| CN107365272A (en) | A kind of novel imidazole class compound and preparation method thereof and application medically | |
| CN115124532B (en) | Rhein and matrine eutectic crystal, preparation method, composition and application thereof | |
| CN102093234B (en) | Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof | |
| CN103183722A (en) | Glyoxalase I inhibitor, preparation method and medical application thereof | |
| CN112778369B (en) | Triazole derivative and preparation method and application thereof | |
| CN101514189B (en) | Glycin diazole tromethamine compound as well as preparation method and medicament application thereof | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN115124420A (en) | Rhein and matrine eutectic crystal hydrate, preparation method, composition and application thereof | |
| CN1729988A (en) | Composite medicine of creatine phosphate sodium and magnesium salt | |
| CN114929682A (en) | Salt of benzothiopyrone compound and preparation method and application thereof | |
| CN113521020B (en) | A solid dosage form of adefovir containing water soluble acid | |
| CN113491668B (en) | Pharmaceutical composition preparation for injection and preparation method and application thereof | |
| CN103570679A (en) | Dabigatran etexilate gluconate, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121128 Assignee: SHANDONG LUYE PHARMACEUTICAL Co.,Ltd. Assignor: Ning Hui Contract record no.: 2014370000117 Denomination of invention: Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof License type: Common License Record date: 20140711 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240418 Address after: Room 202, East Building C, Headquarters Center, No. 23 Guangfu East Street, Houtang Community, Jiangbei Street, Dongyang City, Jinhua City, Zhejiang Province, 322100 Patentee after: Zhejiang Zhongyan Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: Room 202, Study Abroad Building, No. 129 Fuzhou North Road, Shibei District, Qingdao City, Shandong Province, 266034 Patentee before: Ning Hui Country or region before: China |